What’s up? Interesting banterEver notice, when the SP is attempting to move up, the increase of nonsensical banter & arrival of various people who only either bash other poster, management or as like today just random nonsense. Many have read my synopsis before, however imho far more important to repeat, then having to read silly banter. So whats up? The SP while not rocketing, a Quick Look shows a steady increase since the near all time low a month ago. The volume is almost non- existent , so any movement up or down could be quickly changed on news. Looking big picture what news are we expecting? What we know of: The AGM will be soon. That being May 15th. Also in May, the 23rd there will be two abstracts published & available May 23rd, at ASCO, the presentation & further details June 1. In the line- up of waiting for news, is the response from FDA regarding details for inclusion if biomarkers into the MBc phase 3 trial. That update. Could be anytime. Thr request was April 11. With a guideline of response within 75 days. Meaning longest case late June. within means just that. Much close , Q1 reults & update, next Thursday, being May 9th. I always encourage people to listen in. I have missed a few company updates, but not many. A word of caution, some of the FUDsters will put their negative spin on things. Listen for your self. Its your investment & you deserve to give it the appropriate time & attention. My guess..only a guess, there will be another N.R. Prior to the Q1 presentation. Waiting in the wings? Expected updates: The O.S. Results & progress with MBc phase 3 trial Final arrangements for pancreatic cancer. Phase 3 details. The SP is relatively stagnant, because those in the know are waiting. Climbing a small amount. Up 18% last month , since the recent all time low.. The short term folks would be happy..yet no sell off. I have seen this scenario before with other stocks. It creates a very volatile platform for movement. Many are sitting waiting for something. The last few company news releases. Most significant being the expansion of a cohort with Roche, Goblet. Yielded next to zero S.P. Interest. Again, many are waiting on the advancement into phase 3, alongside some form of a business deal. They need that to happen. So, everyone waits. BTW with Q1 coming up next week. The analysts usually issue price target updates & reports , after the meetings. Regardless, point is still the same Onc must have a parter or buyout to progress to phase 3. There are 3-4 known clinical updates pending that will influence the trial parameters & obviously any pharma parter involvement. Onc has come a long way the past year. Im talking clinical development not S.P. Next Thursday @ close of market. Listen in.